@article{10902/36775,
year = {2025},
url = {https://hdl.handle.net/10902/36775},
abstract = {Cannabidiol (CBD) holds promise for managing metabolic diseases, yet enhancing its oral bioavailability and efficacy remains challenging. To address this, we developed polymeric nanoparticles (NPs), using poly(lactic-co-glycolic acid) (PLGA), encapsulating CBD using nanoprecipitation, aiming to create an effective CBD-nanoformulation for metabolic disorder treatment. These NPs (135-265 nm) demonstrated high encapsulation efficiency (EE% = 100%) and sustained release kinetics. Their therapeutic potential was evaluated in an in vitro metabolic syndrome model employing sodium palmitate-induced HepG2 cells. Key assessment parameters included cell viability (MTT assay), glucose uptake, lipid accumulation (Oil Red O staining), triglycerides, cholesterol, HDL-c levels, and gene expression of metabolic regulators. Results showed an IC50 of 9.85 ug/mL for free CBD and 11.26 ug/mL for CBD-loaded NPs. CBD-loaded NPs significantly enhanced glucose uptake, reduced lipid content, lowered triglycerides and total cholesterol, and increased HDL-c levels compared to free CBD. Gene analysis indicated reduced gluconeogenesis via downregulation of PPARy, FOXO-1, PEPCK, and G6Pase and enhanced fatty acid oxidation through CPT-1 upregulation. These findings suggest that CBD-loaded NPs may serve as a novel therapeutic strategy for the management of metabolic disorders, warranting further in vivo studies.},
organization = {The authors especially thank the financial support from the Instituto de Investigación Sanitaria Valdecilla (IDIVAL; INNVAL18/30;
INT22/00029) and Plan Estatal 2021-2023,
Ministerio de Ciencia e Innovación (PID2021-122714OB-
I00).
J. V-B
also acknowledges funding support from
IDIVAL (INT/A21/10, INT/A20/04) and Plan Nacional sobre Drogas (Ministerio de Sanidad, Gobierno de España; 2021I079). L. M-N
is particularly grateful
to the Ministerio de Ciencia e Innovación for pre-doctoral
funding (PRE2022-101521).},
publisher = {John Wiley & Sons},
publisher = {Journal of Biomedical Materials Research Part A, 2025, 113, e37916},
title = {Enhanced metabolic syndrome management through cannabidiol-loaded PLGA nanoparticles: development and in vitro evaluation},
author = {El-Hammadi, Mazen M. and Martín-Navarro, Lucía and Berrocoso, Esther and Álvarez-Fuentes, Josefa and Crespo-Facorro, Benedicto and Suárez-Pereira, Irene and Vázquez Bourgon, Javier and Martín-Banderas, Lucía},
}